R. Yaari

6.9k total citations · 2 hit papers
50 papers, 1.2k citations indexed

About

R. Yaari is a scholar working on Psychiatry and Mental health, Physiology and Nuclear and High Energy Physics. According to data from OpenAlex, R. Yaari has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 15 papers in Physiology and 7 papers in Nuclear and High Energy Physics. Recurrent topics in R. Yaari's work include Dementia and Cognitive Impairment Research (25 papers), Alzheimer's disease research and treatments (14 papers) and High-Energy Particle Collisions Research (7 papers). R. Yaari is often cited by papers focused on Dementia and Cognitive Impairment Research (25 papers), Alzheimer's disease research and treatments (14 papers) and High-Energy Particle Collisions Research (7 papers). R. Yaari collaborates with scholars based in United States, Israel and Australia. R. Yaari's co-authors include Karen C. Holdridge, Rema Raman, Eric M. Reiman, Reisa A. Sperling, Richard J. Caselli, Michael Donohue, Thomas G. Beach, Paul Aisen, Chung‐Kai Sun and Keith A. Johnson and has published in prestigious journals such as New England Journal of Medicine, Physical Review Letters and Neurology.

In The Last Decade

R. Yaari

46 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

2020 201 citations Reisa A. Sperling, Michael Donohue et al. profile →
Trial of Solanezumab in Preclinical Alzheimer’s Disease

2023 186 citations Reisa A. Sperling, Michael Donohue et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Yaari United States	17	533	525	154	151	146	50	1.2k
Mateusz S. Jasielec United States	12	720 1.4×	735 1.4×	279 1.8×	146 1.0×	96 0.7×	17	1.2k
Chung‐Kai Sun United States	12	608 1.1×	602 1.1×	184 1.2×	116 0.8×	90 0.6×	28	1.1k
Qing‐Fei Zhao China	11	540 1.0×	761 1.4×	235 1.5×	172 1.1×	98 0.7×	13	1.6k
Laura Bracco Italy	22	487 0.9×	451 0.9×	219 1.4×	296 2.0×	131 0.9×	40	1.3k
Billy Dunn United States	11	493 0.9×	454 0.9×	118 0.8×	209 1.4×	87 0.6×	22	1.4k
J. Scott Andrews United States	16	569 1.1×	823 1.6×	142 0.9×	154 1.0×	120 0.8×	44	1.5k
S. D. Edland United States	6	581 1.1×	666 1.3×	231 1.5×	149 1.0×	47 0.3×	8	1.0k
Giuseppe Gambina Italy	22	483 0.9×	342 0.7×	172 1.1×	232 1.5×	259 1.8×	50	1.3k
Göran Hagman Sweden	12	557 1.0×	516 1.0×	194 1.3×	125 0.8×	77 0.5×	33	986
Hua Jin China	14	316 0.6×	622 1.2×	155 1.0×	69 0.5×	50 0.3×	43	1.5k

Countries citing papers authored by R. Yaari

Since Specialization

Citations

This map shows the geographic impact of R. Yaari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Yaari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Yaari more than expected).

Fields of papers citing papers by R. Yaari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Yaari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Yaari. The network helps show where R. Yaari may publish in the future.

Co-authorship network of co-authors of R. Yaari

This figure shows the co-authorship network connecting the top 25 collaborators of R. Yaari. A scholar is included among the top collaborators of R. Yaari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Yaari. R. Yaari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yaari, R., Karen C. Holdridge, Alette M. Wessels, et al.. (2025). Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3. Alzheimer s & Dementia. 21(9). e70662–e70662. 4 indexed citations

Shirzadi, Zahra, Aaron P. Schultz, Michael J Properzi, et al.. (2024). Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(4). 869–873. 5 indexed citations

Raman, Rema, Michael Donohue, Karin Ernström, et al.. (2024). Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial. The Journal of Prevention of Alzheimer s Disease. 11(4). 874–880. 2 indexed citations

Sperling, Reisa A., Michael Donohue, Robert A. Rissman, et al.. (2024). Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies. The Journal of Prevention of Alzheimer s Disease. 11(4). 802–813. 24 indexed citations

Rissman, Robert A., Oliver Langford, Rema Raman, et al.. (2024). Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(4). 823–830. 14 indexed citations

Sperling, Reisa A., Michael Donohue, Rema Raman, et al.. (2023). Trial of Solanezumab in Preclinical Alzheimer’s Disease. New England Journal of Medicine. 389(12). 1096–1107. 186 indexed citations breakdown →

Holdridge, Karen C., R. Yaari, Deirdre B. Hoban, Scott W. Andersen, & John R. Sims. (2023). Targeting amyloid β in Alzheimer's disease: Meta‐analysis of low‐dose solanezumab in Alzheimer's disease with mild dementia studies. Alzheimer s & Dementia. 19(10). 4619–4628. 13 indexed citations

Yaari, R., et al.. (2022). Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid. The Journal of Prevention of Alzheimer s Disease. 9(4). 617–624. 5 indexed citations

McDade, Eric, Guoqiao Wang, Yan Li, et al.. (2022). Longitudinal cerebrospinal fluid phosphorylated tau181 and total tau do not reflect tau PET retention in dominantly inherited Alzheimer disease. Alzheimer s & Dementia. 18(S6). 1 indexed citations

10.

Papp, Kathryn V., Dorene M. Rentz, Paul Maruff, et al.. (2021). The Computerized Cognitive Composite (C3) in A4, an Alzheimer's Disease Secondary Prevention Trial. The Journal of Prevention of Alzheimer s Disease. 8(1). 59–67. 41 indexed citations

11.

Amariglio, Rebecca E., Sietske A.M. Sikkes, Gad A. Marshall, et al.. (2021). Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data. The Journal of Prevention of Alzheimer s Disease. 8(3). 257–262. 20 indexed citations

12.

Downing, AnnCatherine M., R. Yaari, Daniel Ball, & Katherine J. Selzler. (2015). BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASE. The Journal of Prevention of Alzheimer s Disease. 3(1). 1–13. 1 indexed citations

13.

Burke, Anna, et al.. (2011). Mild Cognitive Impairment. The Primary Care Companion For CNS Disorders. 13(4). 2 indexed citations

14.

Yaari, R., Adam Fleisher, & Pierre N. Tariot. (2011). Updates to Diagnostic Guidelines for Alzheimer’s Disease. The Primary Care Companion For CNS Disorders. 13(5). 14 indexed citations

15.

Rabins, Peter V., Neill R. Graff‐Radford, Gary W. Small, & R. Yaari. (2009). New Developments in the Treatment of Alzheimer's Disease. The Journal of Clinical Psychiatry. 70(2). 281–290.

16.

Yaari, R. & Pierre N. Tariot. (2008). Combination Therapies for Treating Alzheimer’s Disease. 4(1). 31–31. 1 indexed citations

17.

Yaari, R., et al.. (2008). Non-cholinergic drug development for Alzheimer's disease. Expert Opinion on Drug Discovery. 3(7). 745–760. 5 indexed citations

18.

Yaari, R., et al.. (2007). Density of the Brain, Decline of the Mind. Archives of Neurology. 64(5). 756–756. 10 indexed citations

19.

Caselli, Richard J., Thomas G. Beach, R. Yaari, & Eric M. Reiman. (2006). Alzheimer's Disease A Century Later. The Journal of Clinical Psychiatry. 67(11). 1784–1800. 89 indexed citations

20.

Yaari, R., et al.. (2004). Childhood primary angiitis of the central nervous system: Two biopsy-proven cases. The Journal of Pediatrics. 145(5). 693–697. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact